Literature DB >> 2443612

Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus.

M Trudel1, F Nadon, C Seguin, G Dionne, M Lacroix.   

Abstract

A 7000 Mr cleavage fragment of the F1 subunit that carries the major neutralization epitope has been identified by chemical and enzymatic cleavage of the fusion protein of respiratory syncytial (RS) virus (Long strain) with an efficient RS virus-neutralizing monoclonal antibody. Based on the published mRNA-deduced sequence of the A2 strain, coupled to the hydropathicity profile and prediction of protein conformation, the neutralization epitope has tentatively been localized on the first third of the F1 protein N-terminal, probably in the region of amino acids 215Ser to 236Glu. Analysis of three peptides covering different portions of the 212Cys to 236Glu region of the F1 fusion protein identified a peptide (Cys X 216Asn to 236Glu) that reacted strongly with the neutralizing monoclonal antibody and that was efficient in blocking neutralization and in plaque-reducing assays, confirming that the neutralization epitope was localized in that region. Further analysis with two other synthetic peptides (212Cys to 222Glu and Cys X 221Ile to 236Glu) indicated that the dodecapeptide Ile-Glu-Phe-Gln-Lys-Asn-Asn-Arg-Leu-Leu-Glu mimicked either the whole or a major part of the neutralization epitope. This opens a promising avenue for the simple design of a synthetic peptide vaccine to control RS virus infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443612     DOI: 10.1099/0022-1317-68-9-2273

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus.

Authors:  J A López; C Peñas; B García-Barreno; J A Melero; A Portela
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies.

Authors:  C Palomo; J P Albar; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Antigenic structure of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; R Bustos; C Orvell; M Berois; J Arbiza; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

4.  Comparison of caprine, human and bovine strains of respiratory syncytial virus.

Authors:  M Trudel; F Nadon; C Simard; F Bélanger; R Alain; C Séguin; G Lussier
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 5.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

Review 7.  Respiratory syncytial virus: virology, diagnosis, and vaccination.

Authors:  G L Toms
Journal:  Lung       Date:  1990       Impact factor: 2.584

8.  Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.

Authors:  M E Levely; C A Bannow; C W Smith; J A Nicholas
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

9.  Epitope specificities of human serum antibodies reactive with respiratory syncytial virus fusion protein.

Authors:  B S Robinson; J S Everson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection.

Authors:  H Yamazaki; H Tsutsumi; K Matsuda; K Nagai; P L Ogra; S Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.